Active - does not include patients

Atrial Fibrillation

Location: Solmed Polyclinic (Zagreb)

Study Drug: Experimental drug that slows blood clotting, inhibitor of coagulation factor XI. This experimental drug is expected to have equal effectiveness in preventing stroke with a lower risk of bleeding, the most common side effect of this drug class.

Main Inclusion Criteria: Adult patients diagnosed with atrial fibrillation in the last 12 months who have not planned (or undergone) pulmonary vein isolation procedure (ablation).

Status: Enrolling new patients

Start of patient enrollment: February 2024

Planned completion of patient enrollment: December 2024

Sign up to receive information about future clinical trials of this kind

Related

Cardiology and angiology, Neurology

Postural Orthostatic Tachycardia Syndrome (POTS)

Study Drug: Biological therapy that suppresses the excessive activity of B-lymphocytes that overly produce antibodies associated with this syndrome. The drug is already registered for the treatment of myasthenia gravis.

More
Cardiology and angiology, Endocrinology, diabetes and metabolic diseases

Elevated Cardiovascular Risk (Preventing Heart and Stroke)

Study Drug: A drug from the PCSK9 inhibitor group, already registered for treating elevated lipids. It is available to patients who have had a myocardial infarction and, with existing medications, have excessively high LDL cholesterol. In the context of this study, the drug can be given to patients who have not had a myocardial infarction but are at a high risk of it.

More
Cardiology and angiology

Heart Attack (Myocardial Infarction)

Study Drug: Experimental drug that slows blood clotting, an inhibitor of clotting factor XI. A low dose of this experimental drug is expected to prevent the reformation of clots at the site of previous blood vessel blockage.

More
Cardiology and angiology

Heart Failure with Preserved Ejection Fraction (IL-6 Study)

Study Drug: Experimental drug that reduces inflammation throughout the body, which should strengthen the heart’s function.

More
Cardiology and angiology

Heart Failure with Preserved Ejection Fraction (MRA Study)

Study Drug: Mineralocorticoid receptor antagonist, already registered for the treatment of other diseases.

More
Cardiology and angiology, Endocrinology, diabetes and metabolic diseases

Blood Vessel Blockage (Atherosclerotic Disease) and Elevated Blood Lipids

Study Drug: Experimental drug “transfers” cholesterol from bad particles (LDL) to good particles (HDL) of cholesterol.

More

What our patients say

Poliklinika Solmed

Sonja Milek

“Nije mi žao, imam osjećaj da je pomoglo.”

Poliklinika Solmed

Matea Vidan

“Učestale kontrole nisu mi predstavljale problem. Zapravo sam se i ja osjećala puno sigurnije, kad sam bila svjesna da svakih mjesec dana ipak kontroliramo moje stanje.”

Poliklinika Solmed

Mykyta Monastyrskyi

“Imao sam sumnje, ali liječnici su bili stvarno od pomoći sa svim objašnjenjima.”

Poliklinika Solmed

Zvonimir Rogina

“Uključivanje u naše studije je jednostavno i intuitivno.”

Poliklinika Solmed

Lidija Reškovac

“Izuzetno sam zadovoljna interakcijom – mogu saznati sve o bolesti i liječenju.”

Poliklinika Solmed

Siniša Kvakić

“Prijava putem upitnika na web stranici je veoma jednostavna.”

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations